程序性死亡配体-1在人非小细胞肺癌组织中的表达及临床意义

Expression and clinical significance of programmed death ligang-1 in non-small cell lung cancer

目的探讨程序性死亡配体-1(PD-L1)在人非小细胞肺癌(NSCLC)组织中的表达及临床意义。方法采用Western blot和免疫组织化学染色法检测41例NSCLC患者的肺癌组织、癌旁组织、正常肺组织和15例肺部良性病变患者的正常肺组织中的PD-L1表达,分析NSCLC患者PD-L1表达的影响因素。结果 NSCLC患者肺癌组织中PD-L1阳性表达率为80.49%(33/41),肺良性病变患者正常肺组织中几乎无PD-L1表达。NSCLC患者肺癌组织中PD-L1表达高于癌旁组织及正常肺组织(P<0.05)。PD-L1的表达与肿瘤患者分期、淋巴结转移和远处转移相关(P<0.05),而与肿瘤病理分型、患者年龄、性别、吸烟史及肿瘤大小等无关(P>0.05)。结论 PD-L1在NSCLC组织中显著高表达,在NSCLC进展中发挥重要作用,可能成为NSCLC预后的判断指标及免疫治疗的新靶点。

Objective To study the expression and clinical significance of programmed death ligang‐1 （ PD‐L1 ） in non‐small cell lung cancer （ NSCLC ） . Methods Western blot and immunohistochemistry analysis were used to detect the expressions of PD‐L1 in lung cancer tissues , tumor‐adjacent tissues and normal lung tissues in 41 patients with NSCLC ,and in benign pulmonary lesion（15 cases ） .The influence factors of PD‐L1 expression in the patients with NSCLC were analyzed .Results The positive expression rate of PD‐L1 was 80 .49% in NSCLC tissues ,whereas almost none expression was observed in normal lung tissues of patients with benign pulmonary lesion . The expression of PD‐L1 was significantly higher in NSCLC tissues than that in tumor‐adjacent tissues and normal lung tissues （P0 .05 ） .Conclusion PD‐L1 is highly expressed in NSCLC ,which plays an important role in the development of NSCLC and may serve as a useful predictive marker of prognosis and target of immunotherapy .